Establishment and characterization of cell lines from chromosomal instable colorectal cancer

World Journal of Gastroenterology

Volumn 21, Issue 1, 2015, Pages 164-176

  Maletzki, Claudia ^a   Gock, Michael ^a   Randow, Martin ^a   Klar, Ernst ^a   Huehns, Maja ^a   Prall, Friedrich ^a   Linnebacher, Michael ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Colorectal cancer; Drug response; Individualized medicine; Molecular characterization; Patient derived tumor model; Translational research

Indexed keywords

APC PROTEIN; BETA CATENIN; BIOLOGICAL MARKER; CISPLATIN; CYTOKERATIN; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; PACLITAXEL; PROTEIN P53; RAPAMYCIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

AGED; ANEUPLOIDY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CARCINOGENICITY; CELL GROWTH; CELL STRUCTURE; CHEMOSENSITIVITY; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CPG ISLAND; DNA FINGERPRINTING; DNA METHYLATION; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MICROSATELLITE INSTABILITY; MICROSCOPY; MOUSE; MUTATIONAL ANALYSIS; MYCOPLASMA; NONHUMAN; NUDE MOUSE; PHENOTYPE; QUALITY CONTROL; TUMOR MODEL; TUMOR XENOGRAFT; VERY ELDERLY; VIRUS EXAMINATION; ANIMAL; CANCER STAGING; CELL MOTION; CELL PROLIFERATION; CELL SEPARATION; CELL SHAPE; COLORECTAL NEOPLASMS; DNA MICROARRAY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; IC50; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; TIME; TUMOR CELL LINE; TUMOR INVASION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SEPARATION; CELL SHAPE; CHROMOSOMAL INSTABILITY; COLORECTAL NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLANDS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INHIBITORY CONCENTRATION 50; MICE, NUDE; MICROSATELLITE INSTABILITY; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920878083     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i1.164     Document Type: Article

References (48)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532 [PMID: 2841597 DOI: 10.1056/NEJM198809013190901]
2. Jass JR . Molecular heterogeneity of colorectal cancer: Implications for cancer control. Surg Oncol 2007; 16 Suppl 1: S7-S9 [PMID: 18023574 DOI: 10.1016/j.suronc.2007.10.039]
3. Ostwald C, Linnebacher M, Weirich V, Prall F. Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int J Oncol 2009; 35: 321-327 [PMID: 19578746]
4. Jass JR . Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50 : 113-130 [PMID: 17204026 DOI: 10.1111/j.1365-2559.2006.02549.x]
5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767 [PMID: 2188735 DOI: 10.1016/0092-8674(90)90186-I]
6. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244 : 217-221 [PMID: 2649981 DOI: 10.1126/science.2649981]
7. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-1338 [PMID: 7761852 DOI: 10.1126/science.7761852]
8. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JK, Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996; 13: 343-346 [PMID: 8673134 DOI: 10.1038/ng0796-343]
9. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004; 3: 1221-1224 [PMID: 15467468 DOI: 10.4161/cc.3.10.1164]
10. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113 [PMID: 17932254 DOI: 10.1126/science.1145720]
11. Velculescu VE. Defining the blueprint of the cancer genome. Carcinogenesis 2008; 29 : 1087-1091 [PMID: 18495658 DOI: 10.1093/carcin/bgn096]
12. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-1558 [PMID: 23539594 DOI: 10.1126/science.1235122]
13. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA 2003; 100: 776-781 [PMID: 12552134 DOI: 10.1073/pnas.0334858100]
14. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-649 [PMID: 9872311 DOI: 10.1038/25292]
15. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology 2010; 138: 2059-2072 [PMID: 20420946 DOI: 10.1053/j.gastro.2009.12.065]
16. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008; 7 : 184-190 [PMID: 18621636 DOI: 10.3816/CCC.2008.n.024]
17. Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist 2012; 17 : 14 [PMID: 22210091 DOI: 10.1634/theoncologist.2011-0452]
18. Maletzki C, Stier S, Gruenert U, Gock M, Ostwald C, Prall F, Linnebacher M. Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas. PLoS One 2012; 7: e52485 [PMID: 23300683 DOI: 10.1371/journal.pone.0052485]
19. Poupon MF, Arvelo F, Goguel AF, Bourgeois Y, Jacrot M, Hanania N, Arriagada R, Le Chevalier T. Response of smallcell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst 1993; 85: 2023-2029 [PMID: 7902445 DOI: 10.1093/jnci/85.24.2023]
20. Fielding LP, Arsenault PA, Chapuis PH, Dent O, Gathright B, Hardcastle JD, Hermanek P, Jass JR, Newland RC. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol 1991; 6 : 325-344 [PMID: 1912440 DOI: 10.1111/j.1440-1746.1991.tb00867.x]
21. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-96 [PMID: 18832519 DOI: 10.1136/gut.2008.155473]
22. Masibay A, Mozer TJ, Sprecher C. Promega Corporation reveals primer sequences in its testing kits. J Forensic Sci 2000; 45: 1360-1362 [PMID: 11110204]
23. Klier U, Maletzki C, Klar E, Linnebacher M. Generation of highly pure fusions of colorectal carcinoma and antigen-presenting cells. Langenbecks Arch Surg 2010; 395: 365-371 [PMID: 20309577 DOI: 10.1007/s00423-010-0598-1]
24. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Maspero F, Sauta MG, Beretta GD, Barni S. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer 2013; 12: 145-151 [PMID: 23763824 DOI: 10.1016/j.clcc.2013.04.006]
25. Salgado M, Reboredo M, Mendez JC, Quintero G, Pellón ML, Romero C, Jorge M, Montes AF, Valladares-Ayerbes M, Ramos M, Varela S, Alonso MÁ. Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study. Anticancer Res 2013; 33: 4089-4096 [PMID: 24023354]
26. Kozuch P, Malamud S, Wasserman C, Homel P, Mirzoyev T, Grossbard M. Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer 2009; 8: 38-42 [PMID: 19203895 DOI: 10.3816/CCC.2009.n.006]
27. Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs 2012; 30: 2219-2225 [PMID: 22270257 DOI: 10.1007/s10637-012-9793-y]
28. Swanton C, Tomlinson I, Downward J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 2006; 5: 818-823 [PMID: 16628000 DOI: 10.4161/cc.5.8.2682]
29. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierré A, De Thé H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prévost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 2012; 18: 5314-5328 [PMID: 22825584 DOI: 10.1158/1078-0432.CCR-12-0372]
30. Scott CL, Becker MA, Haluska P, Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol 2013; 3: 295 [PMID: 24363999 DOI: 10.3389/fonc.2013.00295]
31. Puig I, Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argilés G, Vivancos A, Tabernero J, Rojas S, Palmer HG. A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clin Cancer Res 2013; 19: 6787-6801 [PMID: 24170545 DOI: 10.1158/1078-0432.CCR-12-1740]
32. Chiron M, Bagley RG, Pollard J, Mankoo PK, Henry C, Vincent L, Geslin C, Baltes N, Bergstrom DA. Differential antitumor activity of aflibercept and bevacizumab in patientderived xenograft models of colorectal cancer. Mol Cancer Ther 2014; 13: 1636-1644 [PMID: 24688047]
33. Linnebacher M, Maletzki C, Ostwald C, Klier U, Krohn M, Klar E, Prall F. Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer 2010; 10: 362 [PMID: 20615215 DOI: 10.1186/1471-2407-10-362]
34. North German Tumor Bank of Colorectal Cancer. Available from: URL: http://www.northgermantumorbank-crc.de/North-German-Tumor-Bank-CRC/Home.html
35. Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, Saulnier P, Judde JG, Janneau JL, Auger N, Validire P, Dutrillaux B, Praz F, Bellet D, Poupon MF. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 2007; 67: 398-407 [PMID: 17210723 DOI: 10.1158/0008-5472.CAN-06-0594]
36. Lerescu L, Tucureanu C, Caras I, Neagu S, Melinceanu L, Sãlãgeanu A. Primary cell culture of human adenocarcinomas - practical considerations. Roum Arch Microbiol Immunol 2008; 67: 55-66 [PMID: 19496473]
37. Seol HS, Kang HJ, Lee SI, Kim NE, Kim TI, Chun SM, Kim TW, Yu CS, Suh YA, Singh SR, Chang S, Jang SJ. Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor. Cancer Lett 2014; 345 : 56-64 [PMID: 24333725 DOI: 10.1016/j.canlet.2013.11.010]
38. Dempke WC, Heinemann V. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma. Anticancer Res 2010; 30: 4673-4677 [PMID: 21115922]
39. Stec R, Bodnar L, Charkiewicz R, Korniluk J, Rokita M, Smoter M, Ciechowicz M, Chyczewski L, Nikliñski J, Kozlowski W, Szczylik C. K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. Cancer Biol Ther 2012; 13: 1235-1243 [PMID: 22909976 DOI: 10.4161/cbt.21813]
40. Danes BS, Deangelis P, Traganos F, Melamed MR, Alm T. Demonstration of altered cellular DNA content distribution in long-term colon epithelial cell lines with colon cancer genotypes. Scand J Gastroenterol 1988; 23: 840-846 [PMID: 3227300 DOI: 10.3109/00365528809090770]
41. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007; 2 : 329-333 [PMID: 17406593 DOI: 10.1038/nprot.2007.30]
42. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634 [PMID: 18316791 DOI: 10.1200/JCO.2007.14.7116]
43. Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, Lipson EJ, Chapman PB, Diaz LA, Vogelstein B, Nowak MA. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2013; 2: e00747 [PMID: 23805382 DOI: 10.7554/eLife.00747]
44. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19 : 619-625 [PMID: 23584089 DOI: 10.1038/nm.3175]
45. Knijn N, Tol J, Punt CJ. Current issues in the targeted therapy of advanced colorectal cancer. Discov Med 2010; 9: 328-336 [PMID: 20423677]
46. Francipane MG, Lagasse E. mTOR pathway in colorectal cancer: an update. Oncotarget 2014; 5: 49-66 [PMID: 24393708]
47. Gulhati P, Zaytseva YY, Valentino JD, Stevens PD, Kim JT, Sasazuki T, Shirasawa S, Lee EY, Weiss HL, Dong J, Gao T, Evers BM. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. Carcinogenesis 2012; 33 : 1782-1790 [PMID: 22696593 DOI: 10.1093/carcin/bgs203]
48. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22 [PMID: 17613433 DOI: 10.1016/j.ccr.2007.05.008]